市場調査レポート
商品コード
1462288
DKN-01市場:市場規模、予測、新たな洞察-2032年DKN-01 Market Size, Forecast, and Emerging Insight - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
DKN-01市場:市場規模、予測、新たな洞察-2032年 |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
DKN-01はヒト化モノクローナル抗体であり、Dickkopf-1(DKK1)タンパク質に結合してその活性を阻害し、腫瘍微小環境における自然免疫系の活性化と抗腫瘍活性をもたらします。DKK1は、Wnt/β-カテニンおよびPI3キナーゼ/ACTシグナル伝達経路を調節し、骨髄由来抑制細胞の活性を高め、腫瘍細胞上のNK細胞リガンドをダウンレギュレートすることにより、腫瘍細胞のシグナル伝達および免疫抑制的腫瘍微小環境の媒介に重要な役割を果たします。この薬剤は2027年までに市場に参入する見込みです。
今後数年間で、卵巣がんの市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新規アプローチに焦点を当てた治療法を開発し、課題を評価し、DKN-01の優位性に影響を与える可能性のある機会を模索しています。卵巣がんに対する他の新興製品がDKN-01に厳しい市場競争をもたらすと予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。
当レポートでは、主要7ヶ国における卵巣がん治療薬のDKN-01市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。
"DKN-01 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about DKN-01 for ovarian cancer in the seven major markets. A detailed picture of the DKN-01 for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the DKN-01 for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DKN-01 market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.
DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, leading to the activation of the innate immune system in the tumor microenvironment and antitumor activity. DKK1 modulates the Wnt/beta-catenin and PI3kinase/AKT signaling pathways, which have an important role in tumor cell signaling and mediating an immunosuppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells and downregulating NK cell ligands on tumor cells. The drug is expected to enter the market by 2027.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
DKN-01 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of DKN-01 for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.
The report provides the clinical trials information of DKN-01 for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.